Similar Therapeutic Effects of I Seed Radiotherapy and γ-ray Radiotherapy on Lacrimal Gland Adenoid Cystic Carcinoma

Overview

Journal Int J Ophthalmol

Specialty Ophthalmology

Date 2021 Apr 20

PMID 33875946

Citations 5

Authors

Rui Liu

Ji-Tong Shi

Xin Ge

Ben-Tao Yang

Hong Zhang

Jing-Xue Zhang

Jian-Min Ma

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the survival outcomes of patients with lacrimal gland adenoid cystic carcinoma who underwent eye-sparing surgery combined with I seed implantation radiotherapy or local external γ-ray radiotherapy.

Methods: In this retrospective comparative case series, the clinical records of 27 primary and 8 recurrent patients were reviewed. Univariate and multivariate analyses were used to identify risk factors associated with distant metastasis (DM), and the overall survival (OS) after the initial surgery was analyzed.

Results: The median follow-up after radiotherapy was 36mo (range 6-120mo). At the last follow-up after radiotherapy, 26 (74.3%) patients had no evidence of disease, 7 (20%) patients had DM, 2 (5.9%) patients died of DM, and 1 patient with DM was lost to follow-up. Univariate analyses showed that duration of symptoms, bone destruction, T stage classification, and wide excision surgery were risk factors influencing DM (<0.05). The 5-year and 10-year OS rates after the initial surgery were 95.8% and 79.9%, respectively. The 5-year DM-free survival and disease-free survival rates after radiotherapy were 66.4% and 52.7%, respectively.

Conclusion: I seed radiotherapy and local external γ-ray radiotherapy may have similar therapeutic effects in preventing DM. Patients with T1/T2 stage disease have a better prognosis than those with T3/T4 stage disease.

Citing Articles

Adenoid Cystic Carcinoma of the Lacrimal Gland.

Chaaya C, El Haddad G, Abdul Karim F, Daher S J Curr Ophthalmol. 2024; 36(1):1-8.

PMID: 39553321 PMC: 11567613. DOI: 10.4103/joco.joco_231_23.

Prognostic factors for lacrimal gland adenoid cystic carcinoma: a retrospective study in Chinese patients.

Yang L, Jia S, Yang J, Song X, Wang Y, Fan X Int J Ophthalmol. 2024; 17(8):1423-1430.

PMID: 39156780 PMC: 11286454. DOI: 10.18240/ijo.2024.08.06.

Development of Small HN Linked Radionuclide Iodine-125 for Nanocarrier Image Tracing in Mouse Model.

Ma R, Ji C, Shen M, Xu S, Fan G, Wu C Int J Nanomedicine. 2024; 19:1909-1922.

PMID: 38414522 PMC: 10898482. DOI: 10.2147/IJN.S446564.

Treatment of lacrimal gland adenoid cystic carcinoma: a systematic review and Meta-analysis.

Yan H, Liu R, Wang N, Xu L, Guo Q, Li J Int J Ophthalmol. 2024; 17(1):164-172.

PMID: 38239951 PMC: 10754659. DOI: 10.18240/ijo.2024.01.22.

Bevacizumab is an Efficient Therapeutic Approach with Low Side Effects in Patient-Derived Xenografts of Adenoid Cystic Carcinoma of the Lacrimal Gland.

Zhang J, Yan X, Liu R, Wu S, Liu Q, Li J Cancer Manag Res. 2022; 14:1023-1032.

PMID: 35283648 PMC: 8912937. DOI: 10.2147/CMAR.S352623.

References

Liao S, Erickson B, Kapila N, Dubovy S, Tse D . Histopathologic Observations of Eyes in Exenterated Orbits After Neoadjuvant Intra-Arterial Cytoreductive Chemotherapy for Adenoid Cystic Carcinoma of the Lacrimal Gland. Ophthalmic Plast Reconstr Surg. 2020; 37(3):274-279. PMC: 7904959. DOI: 10.1097/IOP.0000000000001808. View

Le Tourneau C, Razak A, Levy C, Calugaru V, Galatoire O, Dendale R . Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland. Br J Ophthalmol. 2010; 95(11):1483-9. DOI: 10.1136/bjo.2010.192351. View

Jeong I, Roh J, Cho K, Choi S, Nam S, Kim S . Risk factors for survival and distant metastasis in 125 patients with head and neck adenoid cystic carcinoma undergoing primary surgery. J Cancer Res Clin Oncol. 2020; 146(5):1343-1350. DOI: 10.1007/s00432-020-03170-5. View

Esmaeli B, Yin V, Hanna E, Kies M, William Jr W, Bell D . Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. Head Neck. 2016; 38(8):1258-62. DOI: 10.1002/hed.24433. View

Tang W, Hei Y, Xiao L . Recurrent orbital space-occupying lesions: a clinicopathologic study of 253 cases. Chin J Cancer Res. 2013; 25(4):423-9. PMC: 3752348. DOI: 10.3978/j.issn.1000-9604.2013.08.04. View

Lee D, Campbell R, Waller R, Ilstrup D . A clinicopathologic study of primary adenoid cystic carcinoma of the lacrimal gland. Ophthalmology. 1985; 92(1):128-34. DOI: 10.1016/s0161-6420(85)34081-2. View

Rapidis A, Givalos N, Gakiopoulou H, Faratzis G, Stavrianos S, Vilos G . Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol. 2005; 41(3):328-35. DOI: 10.1016/j.oraloncology.2004.12.004. View

Chawla B, Kashyap S, Sen S, Bajaj M, Pushker N, Gupta K . Clinicopathologic review of epithelial tumors of the lacrimal gland. Ophthalmic Plast Reconstr Surg. 2013; 29(6):440-5. DOI: 10.1097/IOP.0b013e31829f3a0c. View

Seok J, Lee D, Kim W, Jeong W, Chung E, Jung Y . Lung metastasis in adenoid cystic carcinoma of the head and neck. Head Neck. 2019; 41(11):3976-3983. DOI: 10.1002/hed.25942. View

10.

Zhang M, Fathy C, Breazzano M, Hollar M, Barahimi B . Intra-arterial Chemotherapy for Lacrimal Gland Adenoid Cystic Carcinoma. Int Ophthalmol Clin. 2016; 57(1):143-152. DOI: 10.1097/IIO.0000000000000158. View

11.

Bernardini F, Devoto M, Croxatto J . Epithelial tumors of the lacrimal gland: an update. Curr Opin Ophthalmol. 2008; 19(5):409-13. DOI: 10.1097/ICU.0b013e32830b13e1. View

12.

Pelak M, Walser M, Bachtiary B, Hrbacek J, Lomax A, Kliebsch U . Clinical outcomes of head and neck adenoid cystic carcinoma patients treated with pencil beam-scanning proton therapy. Oral Oncol. 2020; 107:104752. DOI: 10.1016/j.oraloncology.2020.104752. View

13.

Yang J, Zhou C, Wang Y, Fan X, Jia R . Multimodal therapy in the management of lacrimal gland adenoid cystic carcinoma. BMC Ophthalmol. 2019; 19(1):125. PMC: 6556222. DOI: 10.1186/s12886-019-1110-5. View

14.

Wolkow N, Jakobiec F, Lee H, Sutula F . Long-term Outcomes of Globe-Preserving Surgery With Proton Beam Radiation for Adenoid Cystic Carcinoma of the Lacrimal Gland. Am J Ophthalmol. 2018; 195:43-62. DOI: 10.1016/j.ajo.2018.07.024. View

15.

Tse D, Kossler A, Feuer W, Benedetto P . Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma. Ophthalmology. 2013; 120(7):1313-23. PMC: 3702633. DOI: 10.1016/j.ophtha.2013.01.027. View

16.

Gamel J, Font R . Adenoid cystic carcinoma of the lacrimal gland: the clinical significance of a basaloid histologic pattern. Hum Pathol. 1982; 13(3):219-25. DOI: 10.1016/s0046-8177(82)80180-9. View

17.

Hung J, Wei Y, Huang C, Chen L, Fuh C, Liao S . Survival outcomes of eye-sparing surgery for adenoid cystic carcinoma of lacrimal gland. Jpn J Ophthalmol. 2019; 63(4):344-351. DOI: 10.1007/s10384-019-00671-w. View

18.

Ahmad S, Esmaeli B, Williams M, Nguyen J, Fay A, Woog J . American Joint Committee on Cancer classification predicts outcome of patients with lacrimal gland adenoid cystic carcinoma. Ophthalmology. 2009; 116(6):1210-5. DOI: 10.1016/j.ophtha.2008.12.049. View

19.

Esmaeli B, Ahmadi M, Youssef A, Diba R, Amato M, Myers J . Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthalmic Plast Reconstr Surg. 2004; 20(1):22-6. DOI: 10.1097/01.IOP.0000105518.72611.4F. View

20.

Wakisaka S, Nonaka A, Morita Y, Fukui M, Kinoshita K . Adenoid cystic carcinoma with intracranial extension: report of three cases. Neurosurgery. 1990; 26(6):1060-5. DOI: 10.1097/00006123-199006000-00025. View